Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors

Next Previous
Trial Profile

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Izalontamab brengitecan (Primary)
  • Indications Advanced breast cancer; HER2 negative breast cancer; HER2 positive breast cancer; Male breast cancer; Non-small cell lung cancer; Solid tumours; Triple negative breast cancer
  • Focus Adverse reactions
  • Sponsors Sichuan Baili Pharmaceutical

Most Recent Events

  • 09 May 2025 According to a SystImmune media release, company will present data from this study in an oral presentation at the European Society for Medical Oncology (ESMO) Breast Cancer 2025 Annual Congress taking place May 14-May 17 in Munich, Germany.
  • 18 Dec 2024 Planned primary completion date changed from 1 Dec 2024 to 1 jun 2025.
  • 11 Dec 2024 According to a SystImmune media release, Updated results from this clinical trial will be presented at the San Antonio Breast Cancer Symposium (SABCS) 2024, taking place on December 10-13 in San Antonio, Texas.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top